Literature DB >> 11069990

Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

T Imamichi1, S C Berg, H Imamichi, J C Lopez, J A Metcalf, J Falloon, H C Lane.   

Abstract

The combination of an amino acid deletion at codon 67 (delta 67) and Thr-to-Gly change at codon 69 (T69G) in the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is associated with high-level resistance to multiple RT inhibitors. To determine the relative contributions of the delta 67 and T69G mutations on viral fitness, we performed a series of studies of HIV replication using recombinant variants. A high-level 3'-azido-3'-deoxythymidine (AZT)-resistant variant containing delta 67 plus T69G/K70R/L74I/K103N/T215F/K219Q in RT replicated as efficiently as wild-type virus (Wt). In contrast, the construct without delta 67 exhibited impaired replication (23% of growth of Wt). A competitive fitness study failed to reveal any differences in replication rates between the delta 67+T69G/K70R/L74I/K103N/T215F/+ ++K219Q mutant and Wt. Evaluation of proviral DNA sequences over a 3-year period in a patient harboring the multiresistant HIV revealed that the T69G mutation emerged in the context of a D67N/K70R/T215F/K219Q mutant backbone prior to appearance of the delta 67 deletion. To assess the impact of this stepwise accumulation of mutations on viral replication, a series of recombinant variants was constructed and analyzed for replication competence. The T69G mutation was found to confer 2',3'-dideoxyinosine resistance at the expense of fitness. Subsequently, the development of the delta 67 deletion led to a virus with improved replication and high-level AZT resistance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069990      PMCID: PMC113175          DOI: 10.1128/jvi.74.23.10958-10964.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.

Authors:  T Imamichi; T Sinha; H Imamichi; Y M Zhang; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

5.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.

Authors:  P R Meyer; S E Matsuura; A M Mian; A G So; W A Scott
Journal:  Mol Cell       Date:  1999-07       Impact factor: 17.970

6.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

7.  The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.

Authors:  L Ross; M Johnson; N Graham; M Shaefer; M St Clair
Journal:  J Hum Virol       Date:  1999 Sep-Oct

8.  Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group.

Authors:  R Rooke; M Tremblay; H Soudeyns; L DeStephano; X J Yao; M Fanning; J S Montaner; M O'Shaughnessy; K Gelmon; C Tsoukas
Journal:  AIDS       Date:  1989-07       Impact factor: 4.177

9.  Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.

Authors:  L Ross; M Johnson; R G Ferris; S A Short; L R Boone; T E Melby; R Lanier; M Shaefer; M St Clair
Journal:  J Hum Virol       Date:  2000 May-Jun

10.  Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives.

Authors:  T Haertle; C J Carrera; D B Wasson; L C Sowers; D D Richman; D A Carson
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

View more
  38 in total

1.  Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations.

Authors:  Shanmugam Saravanan; Vidya Madhavan; Rami Kantor; Sathasivam Sivamalar; Selvamurthi Gomathi; Sunil S Solomon; Nagalingeswaran Kumarasamy; Davey M Smith; Robert T Schooley; Suniti Solomon; Pachamuthu Balakrishnan
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-21       Impact factor: 2.205

2.  Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.

Authors:  Viktoria Nurpeisov; Selwyn J Hurwitz; Prem L Sharma
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

3.  Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing.

Authors:  Matthew J Gonzales; Elizabeth Johnson; Kathryn M Dupnik; Tomozumi Imamichi; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-01       Impact factor: 3.731

4.  Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.

Authors:  Maya Balamane; Vici Varghese; George L Melikian; W Jeffrey Fessel; David A Katzenstein; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

5.  Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Authors:  Elizabeth Johnston; Mark A Winters; Soo-Yon Rhee; Thomas C Merigan; Celia A Schiffer; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Elizabeth Johnston; Kathryn M Dupnik; Matthew J Gonzales; Mark A Winters; Soo-Yon Rhee; Tomozumi Imamichi; Robert W Shafer
Journal:  AIDS       Date:  2005-04-29       Impact factor: 4.177

7.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness.

Authors:  Terrence W Brann; Robin L Dewar; Min-Kan Jiang; Akram Shah; Kunio Nagashima; Julia A Metcalf; Judith Falloon; H Clifford Lane; Tomozumi Imamichi
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

9.  Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.

Authors:  Paul L Boyer; Tomozumi Imamichi; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Eugene L Asahchop; Maureen Oliveira; Matthew McCallum; Susan M Schader; Yingshan Han; Yudong Quan; Stefan G Sarafianos; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.